Peptides for Healing
Research overview of peptides studied for tissue healing, wound repair, and regeneration. BPC-157, TB-500, and regenerative peptide evidence.
Research Overview
Healing peptides represent a diverse research category spanning wound repair, tissue regeneration, and recovery from injury. The most frequently discussed peptides in this space—BPC-157 and TB-500—have extensive preclinical data but limited human clinical trial evidence.
BPC-157 (Body Protection Compound-157) originates from gastric juice proteins and has been studied in numerous rodent models for tendon, muscle, ligament, and gastrointestinal healing. However, most published research comes from a single research group, raising concerns about independent replication.
TB-500, a fragment of thymosin beta-4, has been studied for wound healing applications. The parent compound (Tβ4) has more extensive research, while the specific fragment marketed as TB-500 has fewer direct studies. Both BPC-157 and TB-500 remain unapproved and are prohibited in sport.
Key Peptides in Healing Research
Body Protection Compound (BPC-157)
Status: Not approved by any regulatory agency
| Research Type | Evidence Level |
|---|---|
| Rodent models | Extensive |
| Human trials | Limited (1-2 small studies) |
| Independent replication | Limited |
Proposed mechanisms: VEGF modulation, nitric oxide system, anti-inflammatory effects
Thymosin Beta-4 / TB-500
Status: Not approved (Tβ4 has some clinical development)
| Research Type | Evidence Level |
|---|---|
| Tβ4 human research | Moderate |
| TB-500 specific | Low |
| Wound healing models | Moderate |
Proposed mechanisms: Actin sequestration, cell migration, anti-inflammatory
GHK-Cu (Copper Peptide)
Status: Available in cosmetic formulations
Primarily studied for skin wound healing and collagen synthesis. Better evidence base for topical applications than systemic use.
Evidence Limitations
Researchers should note:
- Most healing peptides lack Phase 3 clinical trials
- BPC-157 research concentration from single source
- TB-500 often extrapolated from Tβ4 studies
- All are prohibited by WADA in sport
Peptides Studied for Healing
GHK-Cu
ModerateA naturally occurring copper-binding tripeptide with wound healing and skin regeneration properties. Extensively studied globally with moderate-to-high evidence for cosmetic applications.
GHK
ModerateA naturally occurring tripeptide (Gly-His-Lys) with copper-binding affinity and wound healing properties. The base form of GHK without added copper. Endogenous to human plasma where it circulates bound to copper. Declines with age. Most research focuses on the copper-complexed form (GHK-Cu), making evidence for GHK alone limited. Primarily relevant as the precursor to GHK-Cu.
LL-37
ModerateThe only human cathelicidin antimicrobial peptide, discovered at Karolinska Institute in Sweden (1995). A 37-amino acid peptide with broad-spectrum antimicrobial activity and immunomodulatory functions. Extensive mechanistic research supports roles in innate immunity, wound healing, and host defense.
TB-500
ModerateA synthetic fragment of thymosin beta-4 marketed for tissue repair. While the parent compound has Phase 3 clinical research (RGN-259), TB-500 specifically has no published human data.
BPC-157
LowA synthetic peptide derived from human gastric juice protein. Preclinical studies suggest tissue repair properties, but human clinical trial data is extremely limited. A 2025 systematic review of 36 studies found only 1 clinical study.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. The peptides listed may or may not have regulatory approval. Always consult a qualified healthcare provider before making any health decisions.